Active, Not Recruiting A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males NCT06866574 Conditions Anal Cancer, Anal Intraepithelial Neoplasia, Anus Diseases, +34 more Locations Fujian Provincial Center for Disease Control and Prevention — Fuzhou, Fujian, China Sichuan Provincial Center for Disease Control and Prevention — Chengdu, Sichuan, China Yunnan Provincial Center for Disease Control and Prevention — Kunming, Yunnan, China Zhejiang Provincial Center for Disease Control and Prevention — Hangzhou, Zhejiang, China View Trial Details
